Stigma Is The Real Delay In Healthcare

The longer someone waits to seek help, the more their condition progresses, the harder it becomes to intervene, and the easier it becomes to keep waiting. Delay compounds. That’s what makes it so dangerous, and so worth targeting directly. The post Stigma Is The Real Delay In Healthcare appeared first on MedCity News.

Read More

BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition

BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics is a marriage of two rare disease biotech companies. Amicus’s two commercialized products, for the enzyme deficiencies Fabry disease and Pompe disease, are each projected to become blockbuster sellers. The post BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition appeared first on MedCity News.

Read More